---
title: 'Extending the Time Window for Tenecteplase by Effective Reperfusion of Penumbral
  Tissue in Patients with Large Vessel Occlusion (ETERNAL-LVO): Rationale and design
  of a multicenter, prospective, randomized, open-label, blinded-endpoint, controlled
  phase 3 trial'
date: '2024-12-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39654273/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241210175343&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'RATIONALE: The benefit of tenecteplase in the treatment of large vessel
  occlusion (LVO) patients presenting within 24 hours of symptom onset remains ...'
disable_comments: true
---
RATIONALE: The benefit of tenecteplase in the treatment of large vessel occlusion (LVO) patients presenting within 24 hours of symptom onset remains ...